GlassScriptPhysician profile
Bradley P Fox
NPI 1336124247
$58,570.81
in general payments reported to CMS, 2019-2025
23 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,304 · 2020: $2,145 · 2021: $422 · 2022: $6,199 · 2023: $12K · 2024: $16K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $7,949 · Travel and Lodging: $6,933 · Food and Beverage: $2,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,502.50 |
| Consulting Fee | $7,948.75 |
| Travel and Lodging | $6,932.76 |
| Food and Beverage | $2,116.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $45,834.87 | 2022-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $11,232.63 | 2019-2021 | |
| Esperion Therapeutics, INC. | $247.53 | 2021-2022 | |
| Pfizer INC. | $170.91 | 2019-2022 | |
| Axsome Therapeutics, INC. | $153.55 | 2025 | Symbravo |
| Dexcom, INC. | $124.90 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Exact Sciences Corporation | $123.86 | 2025 | |
| Phathom Pharmaceuticals, INC. | $115.29 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $105.88 | 2019 | |
| Novo Nordisk INC | $94.79 | 2023-2024 | Wegovy |
| Lilly USA, LLC | $89.11 | 2019-2022 | |
| Amarin Pharma, INC. | $57.07 | 2019-2021 | |
| Amgen INC. | $50.82 | 2019 | |
| Astellas Pharma Global Development | $41.15 | 2023 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $34.28 | 2021-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.50 | 2019 | |
| Boston Scientific Corporation | $19.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.41 | 2021 | |
| Abbvie INC. | $16.24 | 2021 | |
| Glaxosmithkline, LLC. | $11.01 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.